Has iSENS Stock Passed Its Own Second Quarter From 2022?
The day I reopened iSENS stock I did not start with the price screen. I started with a half-year report from 2022…
Entries on Korean listed drugmakers, biotech, medical devices and healthcare services — earnings, orders, shareholder returns and valuation, read from public disclosures. Not investment advice.
The day I reopened iSENS stock I did not start with the price screen. I started with a half-year report from 2022…
Classys stock closed at 31,350 won on September 8, 2026 (Tue), which puts the market capitalization at 20,451 hundr…
Hanmi Pharmaceutical (KOSPI: 128940) signed two out-licensing agreements this summer with a combined headline value…
Shares closed at KRW 8,560 on September 3, 2026 (Thu), putting the whole company at KRW 637.4 billion, or roughly U…
I keep two numbers for SK Biopharm stock in the same row of my notes, and in the June 2026 quarter they stopped mat…
I keep a short file of buyback announcements that I want to check on later, and Dentium stock has been in it since…
Wegovy. That was the biggest single product line at Chong Kun Dang Pharmaceutical in the first half of 2026, at KRW…
PharmaResearch stock closed at KRW 391,000 on August 19, 2026, which works out to about USD 280 at the exchange rat…
A contract manufacturer with four billion dollars of annual revenue reported a net loss equal to 5.96 percent of th…
I opened Nature Cell stock this morning by clicking on a single spreadsheet cell, capital reserve, before I looked…
One drug at this company was turned down by the US Food and Drug Administration on July 13, 2026.
Two numbers came out of the same quarter, for the same drug, at the same company. One is 61.5 billion won.